NYSE American Has Commenced Delisting Proceedings in the FOXO WS warrants of FOXO Technologies Inc.
17 Mai 2023 - 10:30PM
Business Wire
On May 15, 2023 NYSE American LLC (“NYSE American”) provided
written notice to FOXO Technologies Inc. (NYSEAM: FOXO) (the
“Company” or “FOXO”) that NYSE American had halted trading in the
Company’s warrants, each exercisable for one share of the Company’s
Class A common stock at an exercise price per share of $11.50,
ticker symbol FOXO WS (the “Warrants”), on NYSE American due to the
low trading price of the Warrants. On May 16, 2023, NYSE American
provided written notice to the Company and publicly announced that
NYSE Regulation has determined to commence proceedings to delist
the Warrants and that the Warrants are no longer suitable for
listing pursuant to Section 1001 of the NYSE American Company Guide
due to the low trading price of the Warrants.
Trading in the Company’s Class A common stock, ticker symbol
FOXO, will continue on NYSE American.
As of May 17, 2023, the Warrants that previously traded on the
NYSE American under the symbol FOXO WS may be quoted and traded in
the over-the-counter market.
About FOXO Technologies Inc. (“FOXO”)
FOXO is a biotechnology company dedicated to improving human
health and longevity through the development of cutting-edge
technology and product solutions for various industries, including
life insurance. FOXO's epigenetic technology applies AI to DNA
methylation to identify molecular biomarkers of human health and
aging. FOXO is committed to leveraging the latest advancements in
science and technology to help people live better, longer lives.
For more information about FOXO, visit
www.foxotechnologies.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
for purposes of the “safe harbor” provisions under the United
States Private Securities Litigation Reform Act of 1995. Any
statements other than statements of historical fact contained
herein, including statements about the delisting of the Warrants
from NYSE American, trading of the Warrants in the over-the-counter
market, the continued listing of the Company’s Class A common stock
on NYSE American, and other statements identified by words such as
“will likely result,” “are expected to,” “will continue,” “is
anticipated,” “estimated,” “believe,” “intend,” “plan,”
“projection,” “outlook” or words of similar meaning, but the
absence of these words does not mean that a statement is not
forward-looking. Any such forward-looking statements are based upon
the current beliefs and expectations of the Company’s management
and are inherently subject to significant business, economic and
competitive uncertainties and contingencies, many of which are
difficult to predict and generally beyond the Company’s control.
Many factors could cause actual future events to differ materially
from the forward-looking statements in this press release,
including but not limited to the possibility that the Company will
be unable to satisfy the continued listing requirements of NYSE
American for its Class A common stock and maintain the listing of
the Class A common stock on NYSE American; the risk of changes in
the competitive and highly regulated industries in which FOXO
operates; variations in operating performance across competitors or
changes in laws and regulations affecting FOXO’s business; the
ability to implement FOXO’s business plans, forecasts, and other
expectations; the ability to obtain financing; the risk that FOXO
has a history of losses and may not achieve or maintain
profitability in the future; potential inability of FOXO to
establish or maintain relationships required to advance its goals
or to achieve its commercialization and development plans; the
enforceability of FOXO’s intellectual property, including its
patents and the potential infringement on the intellectual property
rights of others; and the risk of downturns and a changing
regulatory landscape in the highly competitive biotechnology
industry or in the markets or industries in which FOXO operates,
including the highly regulated insurance industry. The foregoing
list of factors is not exhaustive. Readers should carefully
consider the foregoing factors and the other risks and
uncertainties discussed in FOXO’s most recent reports on Forms 10-K
and 10-Q, particularly the “Risk Factors” sections of those
reports, and in other documents FOXO has filed, or will file, with
the SEC. These filings identify and address other important risks
and uncertainties that could cause actual events and results to
differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and FOXO assumes no obligation and do
not intend to update or revise these forward-looking statements,
whether as a result of new information, future events, or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005664/en/
Investor Relations Matthew Hausch, Cody Slach Gateway
Investor Relations (949) 574-3860 FOXO@gatewayir.com
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
FOXO Technologies (AMEX:FOXO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024